SRR12475147
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.580
- MYC_TARGETS_V1+0.560
- MYC_TARGETS_V2+0.550
- G2M_CHECKPOINT+0.530
- UNFOLDED_PROTEIN_RESPONSE+0.370
- MTORC1_SIGNALING+0.290
- DNA_REPAIR+0.280
- MITOTIC_SPINDLE+0.150
- SPERMATOGENESIS+0.120
- OXIDATIVE_PHOSPHORYLATION+0.050
Top 10 suppressed
- IL6_JAK_STAT3_SIGNALING-0.460
- MYOGENESIS-0.440
- INTERFERON_GAMMA_RESPONSE-0.430
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.420
- INTERFERON_ALPHA_RESPONSE-0.390
- ALLOGRAFT_REJECTION-0.380
- COMPLEMENT-0.380
- APICAL_SURFACE-0.350
- HEDGEHOG_SIGNALING-0.340
- COAGULATION-0.330
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_TV5B86ZD | Embryonal tumors | — | 0.949 |
| 2 | BS_N6N147BY | Embryonal tumors | — | 0.928 |
| 3 | TCGA-A1-A0SO-01A-22R-A084-07 | — | E | 0.922 |
| 4 | TCGA-78-7155-01A-11R-2039-07 | — | cohortMD1 | 0.918 |
| 5 | SRR13780247 | — | cohortMD1 | 0.917 |
| 6 | BS_HE57E1RP | medulloblastoma | — | 0.916 |
| 7 | TCGA-AR-A1AH-01A-11R-A12D-07 | — | E | 0.916 |
| 8 | MDT-AP-0714 | Med | Medulloblastoma | 0.915 |
| 9 | BS_D144EJRQ | medulloblastoma | — | 0.913 |
| 10 | BS_5P1TN10Z | Embryonal tumors | — | 0.911 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.580 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.560 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.550 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.530 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.370 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.290 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.280 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.150 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.120 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.050 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.050 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.030 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.010 | Remibrutinib | — uncovered |